BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Poelstra K, Prakash J, Beljaars L. Drug targeting to the diseased liver. Journal of Controlled Release 2012;161:188-97. [DOI: 10.1016/j.jconrel.2012.02.011] [Cited by in Crossref: 101] [Cited by in F6Publishing: 109] [Article Influence: 10.1] [Reference Citation Analysis]
Number Citing Articles
1 Mazumder A, Dwivedi A, Assawapanumat W, Saeeng R, Sungkarat W, Nasongkla N. In vitro galactose-targeted study of RSPP050-loaded micelles against liver hepatocellular carcinoma. Pharm Dev Technol 2022;:1-13. [PMID: 35388736 DOI: 10.1080/10837450.2022.2063891] [Reference Citation Analysis]
2 Zhang S, Cao Y, Xu B, Zhang H, Zhang S, Sun J, Tang Y, Wang Y. An antioxidant nanodrug protects against hepatic ischemia-reperfusion injury by attenuating oxidative stress and inflammation. J Mater Chem B 2022. [PMID: 35389415 DOI: 10.1039/d1tb02689e] [Reference Citation Analysis]
3 Li J, Chen C, Xia T. Understanding Nanomaterial-Liver Interactions to Facilitate the Development of Safer Nanoapplications. Adv Mater 2022;34:e2106456. [PMID: 35029313 DOI: 10.1002/adma.202106456] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
4 Li G, Wang M, Ding T, Wang J, Chen T, Shao Q, Jiang K, Wang L, Yu Y, Pan F, Wang B, Wei X, Qian J, Zhan C. cRGD enables rapid phagocytosis of liposomal vancomycin for intracellular bacterial clearance. Journal of Controlled Release 2022. [DOI: 10.1016/j.jconrel.2022.02.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Salvati A, Poelstra K. Drug Targeting and Nanomedicine: Lessons Learned from Liver Targeting and Opportunities for Drug Innovation. Pharmaceutics 2022;14:217. [DOI: 10.3390/pharmaceutics14010217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Fan N, Zhao J, Zhao W, Shen Y, Song Q, Shum HC, Wang Y, Rong J. Biodegradable celastrol-loaded albumin nanoparticles ameliorate inflammation and lipid accumulation in diet-induced obese mice. Biomater Sci 2022. [PMID: 35019905 DOI: 10.1039/d1bm01637g] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Fang P, Han L, Liu C, Deng S, Zhang E, Gong P, Ren Y, Gu J, He L, Yuan ZX. Dual-Regulated Functionalized Liposome-Nanoparticle Hybrids Loaded with Dexamethasone/TGFβ1-siRNA for Targeted Therapy of Glomerulonephritis. ACS Appl Mater Interfaces 2021. [PMID: 34968038 DOI: 10.1021/acsami.1c20053] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Hsu JC, Du Y, Sengupta A, Dong YC, Mossburg KJ, Bouché M, Maidment ADA, Weljie AM, Cormode DP. Effect of Nanoparticle Synthetic Conditions on Ligand Coating Integrity and Subsequent Nano-Biointeractions. ACS Appl Mater Interfaces 2021;13:58401-10. [PMID: 34846845 DOI: 10.1021/acsami.1c18941] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Yu Y, Xing L, Li L, Wu J, He J, Huang Y. Coordination of rigidity modulation and targeting ligand modification on orally-delivered nanoparticles for the treatment of liver fibrosis. J Control Release 2021;341:215-26. [PMID: 34822908 DOI: 10.1016/j.jconrel.2021.11.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Domb AJ, Sharifzadeh G, Nahum V, Hosseinkhani H. Safety Evaluation of Nanotechnology Products. Pharmaceutics 2021;13:1615. [PMID: 34683908 DOI: 10.3390/pharmaceutics13101615] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Lee AR, Baek SM, Lee SW, Kim TU, Han JE, Bae S, Park SJ, Kim TH, Jeong KS, Choi SK, Park JK. Nuclear VEGFR-2 Expression of Hepatocytes Is Involved in Hepatocyte Proliferation and Liver Regeneration During Chronic Liver Injury. In Vivo 2021;35:1473-83. [PMID: 33910825 DOI: 10.21873/invivo.12400] [Reference Citation Analysis]
12 Shi YS, Li XX, Li HT, Zhang Y. Pelargonidin ameliorates CCl4-induced liver fibrosis by suppressing the ROS-NLRP3-IL-1β axis via activating the Nrf2 pathway. Food Funct 2020;11:5156-65. [PMID: 32432601 DOI: 10.1039/d0fo00660b] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
13 Guan Y, Yao W, Yi K, Zheng C, Lv S, Tao Y, Hei Z, Li M. Nanotheranostics for the Management of Hepatic Ischemia-Reperfusion Injury. Small 2021;17:e2007727. [PMID: 33852769 DOI: 10.1002/smll.202007727] [Cited by in Crossref: 1] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zhang J, Hu X, Zheng G, Yao H, Liang H. In vitro and in vivo antitumor effects of lupeol-loaded galactosylated liposomes. Drug Deliv 2021;28:709-18. [PMID: 33825591 DOI: 10.1080/10717544.2021.1905749] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
15 Moya-Garzon MD, Gomez-Vidal JA, Alejo-Armijo A, Altarejos J, Rodriguez-Madoz JR, Fernandes MX, Salido E, Salido S, Diaz-Gavilan M. Small Molecule-Based Enzyme Inhibitors in the Treatment of Primary Hyperoxalurias. J Pers Med 2021;11:74. [PMID: 33513899 DOI: 10.3390/jpm11020074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
16 Jin Y, Wang H, Yi K, Lv S, Hu H, Li M, Tao Y. Applications of Nanobiomaterials in the Therapy and Imaging of Acute Liver Failure. Nanomicro Lett 2020;13:25. [PMID: 34138224 DOI: 10.1007/s40820-020-00550-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
17 Alanazi SA, Alanazi F, Haq N, Shakeel F, Badran MM, Harisa GI. Lipoproteins-Nanocarriers as a Promising Approach for Targeting Liver Cancer: Present Status and Application Prospects. Curr Drug Deliv 2020;17:826-44. [PMID: 32026776 DOI: 10.2174/1567201817666200206104338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Radwan SAA, El-Maadawy WH, Yousry C, ElMeshad AN, Shoukri RA. Zein/Phospholipid Composite Nanoparticles for Successful Delivery of Gallic Acid into aHSCs: Influence of Size, Surface Charge, and Vitamin A Coupling. Int J Nanomedicine 2020;15:7995-8018. [PMID: 33116514 DOI: 10.2147/IJN.S270242] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
19 Zeng Y, Li H, Li Z, Luo Q, Zhu H, Gu Z, Zhang H, Gong Q, Luo K. Engineered gadolinium-based nanomaterials as cancer imaging agents. Applied Materials Today 2020;20:100686. [DOI: 10.1016/j.apmt.2020.100686] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
20 Xing L, Chang X, Shen L, Zhang C, Fan Y, Cho C, Zhang Z, Jiang H. Progress in drug delivery system for fibrosis therapy. Asian J Pharm Sci 2021;16:47-61. [PMID: 33613729 DOI: 10.1016/j.ajps.2020.06.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
21 Reshitko GS, Yamansarov EY, Evteev SA, Lopatukhina EV, Shkil' DO, Saltykova IV, Lopukhov AV, Kovalev SV, Lobov AN, Kislyakov IV, Burenina OY, Klyachko NL, Garanina AS, Dontsova OA, Ivanenkov YA, Erofeev AS, Gorelkin PV, Beloglazkina EK, Majouga AG. Synthesis and Evaluation of New Trivalent Ligands for Hepatocyte Targeting via the Asialoglycoprotein Receptor. Bioconjug Chem 2020;31:1313-9. [PMID: 32379426 DOI: 10.1021/acs.bioconjchem.0c00202] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
22 Dehshahri A, Sadeghpour H, Mohazzabieh E, Saatchi Avval S, Mohammadinejad R. Targeted double domain nanoplex based on galactosylated polyethylenimine enhanced the delivery of IL ‐12 plasmid. Biotechnol Progress 2020;36. [DOI: 10.1002/btpr.3002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
23 Guillot A, Koob GF, Gao B. Reply to Brewer: Liver-targeted ALDH2 inhibition may reduce alcohol-seeking behaviors with limited side effects. Proc Natl Acad Sci U S A 2020;117:7573-4. [PMID: 32127485 DOI: 10.1073/pnas.2001049117] [Reference Citation Analysis]
24 Li W, Zhou C, Fu Y, Chen T, Liu X, Zhang Z, Gong T. Targeted delivery of hyaluronic acid nanomicelles to hepatic stellate cells in hepatic fibrosis rats. Acta Pharm Sin B 2020;10:693-710. [PMID: 32322471 DOI: 10.1016/j.apsb.2019.07.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 12.0] [Reference Citation Analysis]
25 Poelstra K. Innovative Nanotechnological Formulations to Reach the Hepatic Stellate Cell. Curr Tissue Microenviron Rep 2020;1:13-22. [DOI: 10.1007/s43152-020-00004-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Chen X, Hu X, Hu J, Qiu Z, Yuan M, Zheng G. Celastrol-Loaded Galactosylated Liposomes Effectively Inhibit AKT/c-Met-Triggered Rapid Hepatocarcinogenesis in Mice. Mol Pharm 2020;17:738-47. [PMID: 31904241 DOI: 10.1021/acs.molpharmaceut.9b00428] [Cited by in Crossref: 6] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
27 Jiang S, Prozeller D, Pereira J, Simon J, Han S, Wirsching S, Fichter M, Mottola M, Lieberwirth I, Morsbach S, Mailänder V, Gehring S, Crespy D, Landfester K. Controlling protein interactions in blood for effective liver immunosuppressive therapy by silica nanocapsules. Nanoscale 2020;12:2626-37. [PMID: 31939969 DOI: 10.1039/c9nr09879h] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
28 El-Safy S, Tammam SN, Abdel-Halim M, Ali ME, Youshia J, Shetab Boushehri MA, Lamprecht A, Mansour S. Collagenase loaded chitosan nanoparticles for digestion of the collagenous scar in liver fibrosis: The effect of chitosan intrinsic collagen binding on the success of targeting. Eur J Pharm Biopharm 2020;148:54-66. [PMID: 31945489 DOI: 10.1016/j.ejpb.2020.01.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
29 Guillot A, Ren T, Jourdan T, Pawlosky RJ, Han E, Kim SJ, Zhang L, Koob GF, Gao B. Targeting liver aldehyde dehydrogenase-2 prevents heavy but not moderate alcohol drinking. Proc Natl Acad Sci U S A 2019;116:25974-81. [PMID: 31792171 DOI: 10.1073/pnas.1908137116] [Cited by in Crossref: 11] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
30 Wei B, He M, Cai X, Hou X, Wang Y, Chen J, Lan M, Chen Y, Lou K, Gao F. Vitamin E succinate-grafted-chitosan/chitosan oligosaccharide mixed micelles loaded with C-DMSA for Hg2+ detection and detoxification in rat liver. Int J Nanomedicine 2019;14:6917-32. [PMID: 31695366 DOI: 10.2147/IJN.S213084] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Fu Z, Fan Q, Zhou Y, Zhao Y, He Z. Elimination of Intracellular Calcium Overload by BAPTA-AM-Loaded Liposomes: A Promising Therapeutic Agent for Acute Liver Failure. ACS Appl Mater Interfaces 2019;11:39574-85. [PMID: 31589019 DOI: 10.1021/acsami.9b13690] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
32 Lee AR, Nam K, Lee BJ, Lee SW, Baek SM, Bang JS, Choi SK, Park SJ, Kim TH, Jeong KS, Lee DY, Park JK. Hepatic Cellular Distribution of Silica Nanoparticles by Surface Energy Modification. Int J Mol Sci 2019;20:E3812. [PMID: 31387201 DOI: 10.3390/ijms20153812] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
33 Witzigmann D, Uhl P, Sieber S, Kaufman C, Einfalt T, Schöneweis K, Grossen P, Buck J, Ni Y, Schenk SH, Hussner J, Meyer Zu Schwabedissen HE, Québatte G, Mier W, Urban S, Huwyler J. Optimization-by-design of hepatotropic lipid nanoparticles targeting the sodium-taurocholate cotransporting polypeptide. Elife 2019;8:e42276. [PMID: 31333191 DOI: 10.7554/eLife.42276] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
34 Durymanov M, Permyakova A, Sene S, Guo A, Kroll C, Giménez-marqués M, Serre C, Reineke J. Cellular Uptake, Intracellular Trafficking, and Stability of Biocompatible Metal-Organic Framework (MOF) Particles in Kupffer Cells. Mol Pharmaceutics 2019;16:2315-25. [DOI: 10.1021/acs.molpharmaceut.8b01185] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
35 Sieber S, Grossen P, Uhl P, Detampel P, Mier W, Witzigmann D, Huwyler J. Zebrafish as a predictive screening model to assess macrophage clearance of liposomes in vivo. Nanomedicine: Nanotechnology, Biology and Medicine 2019;17:82-93. [DOI: 10.1016/j.nano.2018.11.017] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
36 Kim B, Pena CD, Auguste DT. Targeted Lipid Nanoemulsions Encapsulating Epigenetic Drugs Exhibit Selective Cytotoxicity on CDH1 /FOXM1 + Triple Negative Breast Cancer Cells. Mol Pharmaceutics 2019;16:1813-26. [DOI: 10.1021/acs.molpharmaceut.8b01065] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
37 Patil S, Ujalambkar V, Rathore A, Rojatkar S, Pokharkar V. Galangin loaded galactosylated pluronic F68 polymeric micelles for liver targeting. Biomed Pharmacother 2019;112:108691. [PMID: 30798131 DOI: 10.1016/j.biopha.2019.108691] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
38 Zai W, Chen W, Wu Z, Jin X, Fan J, Zhang X, Luan J, Tang S, Mei X, Hao Q, Liu H, Ju D. Targeted Interleukin-22 Gene Delivery in the Liver by Polymetformin and Penetratin-Based Hybrid Nanoparticles to Treat Nonalcoholic Fatty Liver Disease. ACS Appl Mater Interfaces 2019;11:4842-57. [PMID: 30628769 DOI: 10.1021/acsami.8b19717] [Cited by in Crossref: 15] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
39 Morsy MA, Nair AB. Prevention of rat liver fibrosis by selective targeting of hepatic stellate cells using hesperidin carriers. International Journal of Pharmaceutics 2018;552:241-50. [DOI: 10.1016/j.ijpharm.2018.10.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
40 Zhao L, Li Y, Pei D, Huang Q, Zhang H, Yang Z, Li F, Shi T. Glycopolymers/PEI complexes as serum-tolerant vectors for enhanced gene delivery to hepatocytes. Carbohydr Polym 2019;205:167-75. [PMID: 30446092 DOI: 10.1016/j.carbpol.2018.10.036] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
41 Fernandez-piñeiro I, Alvarez-trabado J, Márquez J, Badiola I, Sanchez A. Xanthan gum-functionalised span nanoparticles for gene targeting to endothelial cells. Colloids and Surfaces B: Biointerfaces 2018;170:411-20. [DOI: 10.1016/j.colsurfb.2018.06.048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
42 Dhoke DM, Basaiyye SS, Khedekar PB. Development and characterization of L-HSA conjugated PLGA nanoparticle for hepatocyte targeted delivery of antiviral drug. Journal of Drug Delivery Science and Technology 2018;47:77-94. [DOI: 10.1016/j.jddst.2018.06.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
43 Qiao J, Fan Q, Xing L, Cui P, He Y, Zhu J, Wang L, Pang T, Oh Y, Zhang C, Jiang H. Vitamin A-decorated biocompatible micelles for chemogene therapy of liver fibrosis. Journal of Controlled Release 2018;283:113-25. [DOI: 10.1016/j.jconrel.2018.05.032] [Cited by in Crossref: 27] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
44 e Silva ATM, Maia ALC, de Oliveira Silva J, de Barros ALB, Soares DCF, de Magalhães MTQ, José Alves R, Ramaldes GA. Synthesis of cholesterol-based neoglycoconjugates and their use in the preparation of liposomes for active liver targeting. Carbohydrate Research 2018;465:52-7. [DOI: 10.1016/j.carres.2018.06.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
45 Lai C, Li C, Luo X, Liu M, Liu X, Hu L, Kang L, Qiu Q, Deng Y, Song Y. Use of Dual-Ligand Modification in Kupffer Cell-Targeted Liposomes To Examine the Contribution of Kupffer Cells to Accelerated Blood Clearance Phenomenon. Mol Pharm 2018;15:2548-58. [PMID: 29768009 DOI: 10.1021/acs.molpharmaceut.8b00042] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
46 El-Mezayen NS, El-Hadidy WF, El-Refaie WM, Shalaby TI, Khattab MM, El-Khatib AS. Oral vitamin-A-coupled valsartan nanomedicine: High hepatic stellate cell receptors accessibility and prolonged enterohepatic residence. J Control Release 2018;283:32-44. [PMID: 29792888 DOI: 10.1016/j.jconrel.2018.05.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
47 Bourquin J, Milosevic A, Hauser D, Lehner R, Blank F, Petri-Fink A, Rothen-Rutishauser B. Biodistribution, Clearance, and Long-Term Fate of Clinically Relevant Nanomaterials. Adv Mater 2018;30:e1704307. [PMID: 29389049 DOI: 10.1002/adma.201704307] [Cited by in Crossref: 173] [Cited by in F6Publishing: 166] [Article Influence: 43.3] [Reference Citation Analysis]
48 Pireddu R, Pibiri M, Valenti D, Sinico C, Fadda AM, Simbula G, Lai F. A novel lactoferrin-modified stealth liposome for hepatoma-delivery of triiodothyronine. Int J Pharm 2018;537:257-67. [PMID: 29294323 DOI: 10.1016/j.ijpharm.2017.12.048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
49 Alsaggar M, Liu D. Organ-based drug delivery. J Drug Target 2018;26:385-97. [PMID: 29419330 DOI: 10.1080/1061186X.2018.1437919] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
50 Qu K, Liu T, Lin T, Zhang X, Cui R, Liu S, Meng F, Zhang J, Tai M, Wan Y, Liu C. Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis? Oncotarget 2016;7:67650-60. [PMID: 27588502 DOI: 10.18632/oncotarget.11767] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
51 Yu F, Selva Kumar ND, Choudhury D, Foo LC, Ng SH. Microfluidic platforms for modeling biological barriers in the circulatory system. Drug Discov Today 2018;23:815-29. [PMID: 29357288 DOI: 10.1016/j.drudis.2018.01.036] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
52 Kaneko K, Ishihara T, Du Toit L. Development of liver-specific ribavirin-loaded nanoparticles with reduced cytotoxicity. Cogent Medicine 2017;4:1418133. [DOI: 10.1080/2331205x.2017.1418133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
53 Collado Camps E, Brock R. An opportunistic route to success: Towards a change of paradigm to fully exploit the potential of cell-penetrating peptides. Bioorg Med Chem 2018;26:2780-7. [PMID: 29157727 DOI: 10.1016/j.bmc.2017.11.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
54 Yazdani S, Bansal R, Prakash J. Drug targeting to myofibroblasts: Implications for fibrosis and cancer. Adv Drug Deliv Rev 2017;121:101-16. [PMID: 28720422 DOI: 10.1016/j.addr.2017.07.010] [Cited by in Crossref: 86] [Cited by in F6Publishing: 84] [Article Influence: 17.2] [Reference Citation Analysis]
55 Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev 2017;121:27-42. [PMID: 28506744 DOI: 10.1016/j.addr.2017.05.007] [Cited by in Crossref: 488] [Cited by in F6Publishing: 477] [Article Influence: 97.6] [Reference Citation Analysis]
56 El-mezayen NS, El-hadidy WF, El-refaie WM, Shalaby T, Khattab MM, El-khatib AS. Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: A novel strategy with potent efficacy in experimental liver fibrosis. Journal of Controlled Release 2017;266:226-37. [DOI: 10.1016/j.jconrel.2017.09.035] [Cited by in Crossref: 17] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
57 Chen J, Chen Y, Cheng Y, Gao Y, Zheng P, Li C, Tong Y, Li Z, Luo W, Chen Z. Modifying glycyrrhetinic acid liposomes with liver-targeting ligand of galactosylated derivative: preparation and evaluations. Oncotarget 2017;8:102046-66. [PMID: 29254224 DOI: 10.18632/oncotarget.22143] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
58 Guo L, Luo S, Du Z, Zhou M, Li P, Fu Y, Sun X, Huang Y, Zhang Z. Targeted delivery of celastrol to mesangial cells is effective against mesangioproliferative glomerulonephritis. Nat Commun 2017;8:878. [PMID: 29026082 DOI: 10.1038/s41467-017-00834-8] [Cited by in Crossref: 74] [Cited by in F6Publishing: 94] [Article Influence: 14.8] [Reference Citation Analysis]
59 Riber CF, Andersen AHF, Rolskov LA, Zuwala K, Gajda P, Løvschall KB, Dagnæs-Hansen F, Banda DH, Pietschmann T, Tolstrup M, Zelikin AN. Synthetic Polymer with a Structure-Driven Hepatic Deposition and Curative Pharmacological Activity in Hepatic Cells. ACS Macro Lett 2017;6:935-40. [PMID: 35650894 DOI: 10.1021/acsmacrolett.7b00471] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
60 Gao YY, Chen H, Zhou YY, Wang LT, Hou Y, Xia XH, Ding Y. Intraorgan Targeting of Gold Conjugates for Precise Liver Cancer Treatment. ACS Appl Mater Interfaces 2017;9:31458-68. [PMID: 28838233 DOI: 10.1021/acsami.7b08969] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
61 Sajeesh S, Choe JY, Lee DK. Core-shell hybrid nanostructured delivery platforms for advanced RNAi therapeutics. Nanomedicine (Lond) 2017;12:2271-86. [PMID: 28868966 DOI: 10.2217/nnm-2017-0174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
62 Kiene K, Schenk SH, Porta F, Ernst A, Witzigmann D, Grossen P, Huwyler J. PDMS-b-PMOXA polymersomes for hepatocyte targeting and assessment of toxicity. Eur J Pharm Biopharm 2017;119:322-32. [PMID: 28720487 DOI: 10.1016/j.ejpb.2017.07.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
63 Cavallaro G, Farra R, Craparo EF, Sardo C, Porsio B, Giammona G, Perrone F, Grassi M, Pozzato G, Grassi G, Dapas B. Galactosylated polyaspartamide copolymers for siRNA targeted delivery to hepatocellular carcinoma cells. International Journal of Pharmaceutics 2017;525:397-406. [DOI: 10.1016/j.ijpharm.2017.01.034] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
64 Venuto CS, Markatou M, Woolwine-Cunningham Y, Furlage R, Ocque AJ, DiFrancesco R, Dumas EO, Wallace PK, Morse GD, Talal AH. Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling Techniques. Antimicrob Agents Chemother 2017;61:e02283-16. [PMID: 28264852 DOI: 10.1128/AAC.02283-16] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
65 Pranatharthiharan S, Patel MD, Malshe VC, Pujari V, Gorakshakar A, Madkaikar M, Ghosh K, Devarajan PV. Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma. Drug Deliv 2017;24:20-9. [PMID: 28155331 DOI: 10.1080/10717544.2016.1225856] [Cited by in Crossref: 43] [Cited by in F6Publishing: 49] [Article Influence: 8.6] [Reference Citation Analysis]
66 Thao LQ, Lee C, Kim B, Lee S, Kim TH, Kim JO, Lee ES, Oh KT, Choi H, Yoo SD, Youn YS. Doxorubicin and paclitaxel co-bound lactosylated albumin nanoparticles having targetability to hepatocellular carcinoma. Colloids and Surfaces B: Biointerfaces 2017;152:183-91. [DOI: 10.1016/j.colsurfb.2017.01.017] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
67 Liu X, Han M, Xu J, Geng S, Zhang Y, Ye X, Gou J, Yin T, He H, Tang X. Asialoglycoprotein receptor-targeted liposomes loaded with a norcantharimide derivative for hepatocyte-selective targeting. International Journal of Pharmaceutics 2017;520:98-110. [DOI: 10.1016/j.ijpharm.2017.02.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
68 Chen F, Zhang J, He Y, Fang X, Wang Y, Chen M. Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA. Biomater Sci 2016;4:167-82. [PMID: 26484363 DOI: 10.1039/c5bm00224a] [Cited by in Crossref: 39] [Cited by in F6Publishing: 46] [Article Influence: 7.8] [Reference Citation Analysis]
69 Huang X, Leroux J, Castagner B. Well-Defined Multivalent Ligands for Hepatocytes Targeting via Asialoglycoprotein Receptor. Bioconjugate Chem 2017;28:283-95. [DOI: 10.1021/acs.bioconjchem.6b00651] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 7.7] [Reference Citation Analysis]
70 Steiger C, Hermann C, Meinel L. Localized delivery of carbon monoxide. Eur J Pharm Biopharm 2017;118:3-12. [PMID: 27836646 DOI: 10.1016/j.ejpb.2016.11.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
71 Fang XB, Xu YQ, Chan HF, Wang CM, Zheng Q, Xiao F, Chen MW. A Redox-Sensitive and RAGE-Targeting Nanocarrier for Hepatocellular Carcinoma Therapy. Mol Pharm 2016;13:3613-25. [PMID: 27768322 DOI: 10.1021/acs.molpharmaceut.6b00116] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
72 Wu L, Mao C, Ming X. Modulation of Bcl-x Alternative Splicing Induces Apoptosis of Human Hepatic Stellate Cells. Biomed Res Int. 2016;2016:7478650. [PMID: 27579319 DOI: 10.1155/2016/7478650] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
73 Liu Z, Niu D, Zhang J, Zhang W, Yao Y, Li P, Gong J. Amphiphilic core-shell nanoparticles containing dense polyethyleneimine shells for efficient delivery of microRNA to Kupffer cells. Int J Nanomedicine 2016;11:2785-97. [PMID: 27366061 DOI: 10.2147/IJN.S101251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
74 Kuai R, Li D, Chen YE, Moon JJ, Schwendeman A. High-Density Lipoproteins: Nature's Multifunctional Nanoparticles. ACS Nano 2016;10:3015-41. [PMID: 26889958 DOI: 10.1021/acsnano.5b07522] [Cited by in Crossref: 181] [Cited by in F6Publishing: 177] [Article Influence: 30.2] [Reference Citation Analysis]
75 Anirudhan TS, Binusreejayan. Dextran based nanosized carrier for the controlled and targeted delivery of curcumin to liver cancer cells. Int J Biol Macromol 2016;88:222-35. [PMID: 27012895 DOI: 10.1016/j.ijbiomac.2016.03.040] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
76 Schon HT, Bartneck M, Borkham-Kamphorst E, Nattermann J, Lammers T, Tacke F, Weiskirchen R. Pharmacological Intervention in Hepatic Stellate Cell Activation and Hepatic Fibrosis. Front Pharmacol 2016;7:33. [PMID: 26941644 DOI: 10.3389/fphar.2016.00033] [Cited by in Crossref: 44] [Cited by in F6Publishing: 59] [Article Influence: 7.3] [Reference Citation Analysis]
77 Zhang YN, Poon W, Tavares AJ, McGilvray ID, Chan WCW. Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination. J Control Release 2016;240:332-48. [PMID: 26774224 DOI: 10.1016/j.jconrel.2016.01.020] [Cited by in Crossref: 404] [Cited by in F6Publishing: 539] [Article Influence: 67.3] [Reference Citation Analysis]
78 Zhang X, Ng HLH, Lu A, Lin C, Zhou L, Lin G, Zhang Y, Yang Z, Zhang H. Drug delivery system targeting advanced hepatocellular carcinoma: Current and future. Nanomedicine. 2016;12:853-869. [PMID: 26772424 DOI: 10.1016/j.nano.2015.12.381] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 11.0] [Reference Citation Analysis]
79 Muhammad N, Wang X, Wang K, Zhu C, Zhu Z, Jiao Y, Guo Z. Dual-drug loaded nanoformulation with a galactosamine homing moiety for liver-targeted anticancer therapy. Dalton Trans 2016;45:13169-78. [DOI: 10.1039/c6dt01434h] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
80 Du C, Li L, Wang H, Zhang J, Yang X, Li C, Qiao R. Hepatocyte targeting and sustained release activity of water-soluble anti-HBV prodrug: Lactobionic acid grafted chitosan–lamivudine conjugate. Reactive and Functional Polymers 2016;98:48-55. [DOI: 10.1016/j.reactfunctpolym.2015.11.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
81 Li Y, Zhu C. Enhanced hepatic-targeted delivery via oral administration using nanoliposomes functionalized with a novel DSPE–PEG–cholic acid conjugate. RSC Adv 2016;6:28110-20. [DOI: 10.1039/c5ra28018d] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
82 Bondì ML, Scala A, Sortino G, Amore E, Botto C, Azzolina A, Balasus D, Cervello M, Mazzaglia A. Nanoassemblies Based on Supramolecular Complexes of Nonionic Amphiphilic Cyclodextrin and Sorafenib as Effective Weapons to Kill Human HCC Cells. Biomacromolecules 2015;16:3784-91. [DOI: 10.1021/acs.biomac.5b01082] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
83 Witzigmann D, Quagliata L, Schenk SH, Quintavalle C, Terracciano LM, Huwyler J. Variable asialoglycoprotein receptor 1 expression in liver disease: Implications for therapeutic intervention: ASGR1 expression in liver disease. Hepatol Res 2016;46:686-96. [DOI: 10.1111/hepr.12599] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
84 Taguchi K, Yamasaki K, Seo H, Otagiri M. Potential Use of Biological Proteins for Liver Failure Therapy. Pharmaceutics 2015;7:255-74. [PMID: 26404356 DOI: 10.3390/pharmaceutics7030255] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
85 Zhang J, Zhang M, Ji J, Fang X, Pan X, Wang Y, Wu C, Chen M. Glycyrrhetinic Acid-Mediated Polymeric Drug Delivery Targeting the Acidic Microenvironment of Hepatocellular Carcinoma. Pharm Res 2015;32:3376-90. [PMID: 26148773 DOI: 10.1007/s11095-015-1714-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
86 Guo H, Sun S, Yang Z, Tang X, Wang Y. Strategies for ribavirin prodrugs and delivery systems for reducing the side-effect hemolysis and enhancing their therapeutic effect. Journal of Controlled Release 2015;209:27-36. [DOI: 10.1016/j.jconrel.2015.04.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
87 D'souza AA, Devarajan PV. Asialoglycoprotein receptor mediated hepatocyte targeting — Strategies and applications. Journal of Controlled Release 2015;203:126-39. [DOI: 10.1016/j.jconrel.2015.02.022] [Cited by in Crossref: 210] [Cited by in F6Publishing: 243] [Article Influence: 30.0] [Reference Citation Analysis]
88 Delire B, Stärkel P, Leclercq I. Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development. J Clin Transl Hepatol 2015;3:53-66. [PMID: 26357635 DOI: 10.14218/JCTH.2014.00035] [Cited by in Crossref: 91] [Cited by in F6Publishing: 73] [Article Influence: 13.0] [Reference Citation Analysis]
89 Wang H, Thorling CA, Liang X, Bridle KR, Grice JE, Zhu Y, Crawford DHG, Xu ZP, Liu X, Roberts MS. Diagnostic imaging and therapeutic application of nanoparticles targeting the liver. J Mater Chem B 2015;3:939-58. [PMID: 32261972 DOI: 10.1039/c4tb01611d] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 9.6] [Reference Citation Analysis]
90 Zhang Q, Zhang X, Chen T, Wang X, Fu Y, Jin Y, Sun X, Gong T, Zhang Z. A safe and efficient hepatocyte-selective carrier system based on myristoylated preS1/21-47 domain of hepatitis B virus. Nanoscale 2015;7:9298-310. [DOI: 10.1039/c4nr04730c] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
91 Liang X, Grice JE, Zhu Y, Liu D, Sanchez WY, Li Z, Crawford DH, Le Couteur DG, Cogger VC, Liu X, Xu ZP, Roberts MS. Intravital multiphoton imaging of the selective uptake of water-dispersible quantum dots into sinusoidal liver cells. Small 2015;11:1711-20. [PMID: 25504510 DOI: 10.1002/smll.201402698] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
92 Bartneck M, Scheyda KM, Warzecha KT, Rizzo LY, Hittatiya K, Luedde T, Storm G, Trautwein C, Lammers T, Tacke F. Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases. Biomaterials 2015;37:367-82. [PMID: 25453965 DOI: 10.1016/j.biomaterials.2014.10.030] [Cited by in Crossref: 74] [Cited by in F6Publishing: 86] [Article Influence: 9.3] [Reference Citation Analysis]
93 Ishihara T, Kaneko K, Ishihara T, Mizushima T. Development of biodegradable nanoparticles for liver-specific ribavirin delivery. J Pharm Sci 2014;103:4005-11. [PMID: 25335768 DOI: 10.1002/jps.24219] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
94 Zhang X, Zhang Q, Peng Q, Zhou J, Liao L, Sun X, Zhang L, Gong T. Hepatitis B virus preS1-derived lipopeptide functionalized liposomes for targeting of hepatic cells. Biomaterials 2014;35:6130-41. [DOI: 10.1016/j.biomaterials.2014.04.037] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
95 Craparo EF, Sardo C, Serio R, Zizzo MG, Bondì ML, Giammona G, Cavallaro G. Galactosylated polymeric carriers for liver targeting of sorafenib. International Journal of Pharmaceutics 2014;466:172-80. [DOI: 10.1016/j.ijpharm.2014.02.047] [Cited by in Crossref: 52] [Cited by in F6Publishing: 59] [Article Influence: 6.5] [Reference Citation Analysis]
96 Fiume L, Manerba M, Di Stefano G. Albumin-drug conjugates in the treatment of hepatic disorders. Expert Opin Drug Deliv 2014;11:1203-17. [PMID: 24773257 DOI: 10.1517/17425247.2014.913567] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
97 Ruan G, Zhang T, Li L, Zhang X, Shen Y, Tabata Y, Gao J. Hepatic-Targeted Gene Delivery Using Cationic Mannan Vehicle. Mol Pharmaceutics 2014;11:3322-9. [DOI: 10.1021/mp5000899] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
98 Hafner A, Lovrić J, Lakoš GP, Pepić I. Nanotherapeutics in the EU: an overview on current state and future directions. Int J Nanomedicine 2014;9:1005-23. [PMID: 24600222 DOI: 10.2147/IJN.S55359] [Cited by in Crossref: 34] [Cited by in F6Publishing: 58] [Article Influence: 4.3] [Reference Citation Analysis]
99 Detampel P, Witzigmann D, Krähenbühl S, Huwyler J. Hepatocyte targeting using pegylated asialofetuin-conjugated liposomes. Journal of Drug Targeting 2013;22:232-41. [DOI: 10.3109/1061186x.2013.860982] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
100 Poelstra K, Beljaars L, Melgert BN. Cell-specific delivery of biologicals: problems, pitfalls and possibilities of antifibrotic compounds in the liver. Drug Discovery Today 2013;18:1237-42. [DOI: 10.1016/j.drudis.2013.05.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
101 Xiao Y, Zhang H, Zhang Z, Yan M, Lei M, Zeng K, Zhao C. Synthesis of novel tetravalent galactosylated DTPA-DSPE and study on hepatocyte-targeting efficiency in vitro and in vivo. Int J Nanomedicine 2013;8:3033-50. [PMID: 23976853 DOI: 10.2147/IJN.S47495] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
102 Ikeda Y, Kubota D, Nagasaki Y. Design of sugar–oligonucleotide conjugates installed gold nanoparticle for effective delivery to hepatic parenchymal cells. Colloid Polym Sci 2013;291:2959-64. [DOI: 10.1007/s00396-013-3029-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
103 Wilson GS, Tian A, Hebbard L, Duan W, George J, Li X, Qiao L. Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro. Cancer Lett. 2013;341:224-230. [PMID: 23941832 DOI: 10.1016/j.canlet.2013.08.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
104 Hu Y, Haynes MT, Wang Y, Liu F, Huang L. A highly efficient synthetic vector: nonhydrodynamic delivery of DNA to hepatocyte nuclei in vivo. ACS Nano 2013;7:5376-84. [PMID: 23647441 DOI: 10.1021/nn4012384] [Cited by in Crossref: 89] [Cited by in F6Publishing: 82] [Article Influence: 9.9] [Reference Citation Analysis]
105 Craparo EF, Triolo D, Pitarresi G, Giammona G, Cavallaro G. Galactosylated micelles for a ribavirin prodrug targeting to hepatocytes. Biomacromolecules 2013;14:1838-49. [PMID: 23621358 DOI: 10.1021/bm4002409] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
106 Thibault PA, Wilson JA. Targeting miRNAs to treat Hepatitis C Virus infections and liver pathology: Inhibiting the virus and altering the host. Pharmacol Res 2013;75:48-59. [PMID: 23541631 DOI: 10.1016/j.phrs.2013.03.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
107 Crommelin DJ, Florence AT. Towards more effective advanced drug delivery systems. Int J Pharm 2013;454:496-511. [PMID: 23415662 DOI: 10.1016/j.ijpharm.2013.02.020] [Cited by in Crossref: 94] [Cited by in F6Publishing: 94] [Article Influence: 10.4] [Reference Citation Analysis]
108 Moles A, Sanchez AM, Banks PS, Murphy LB, Luli S, Borthwick L, Fisher A, O'Reilly S, van Laar JM, White SA, Perkins ND, Burt AD, Mann DA, Oakley F. Inhibition of RelA-Ser536 phosphorylation by a competing peptide reduces mouse liver fibrosis without blocking the innate immune response. Hepatology 2013;57:817-28. [PMID: 22996371 DOI: 10.1002/hep.26068] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
109 Juliano RL, Carver K, Cao C, Ming X. Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides. J Drug Target 2013;21:27-43. [PMID: 23163768 DOI: 10.3109/1061186X.2012.740674] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 5.8] [Reference Citation Analysis]